Literature DB >> 16421130

CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging.

Y A L Pijnenburg1, S N M Schoonenboom, F Barkhof, D L Knol, C Mulder, G J Van Kamp, J C Van Swieten, P Scheltens.   

Abstract

In order to better understand the large variation in cerebrospinal fluid (CSF) tau and amyloid-beta(1-42) (Abeta42) in frontotemporal lobar degeneration (FTLD), relations between these biomarkers and clinical parameters, neuroimaging characteristics, and apolipoprotein E (ApoE) genotype were studied in 31 patients with FTLD, including 16 patients with the frontal variant and 15 with the temporal variant. CSF tau was highest in FTLD with predominant temporal involvement. In the frontal subgroup, CSF tau level was influenced by the number of ApoE epsilon3 alleles. In the temporal subgroup, CSF tau level was dependent on a combination of CSF Abeta42, age, disease duration, and disease severity. No relation with degree of atrophy or asymmetry on neuroimaging could be established. CSF Abeta42 variability remained unexplained. Future research could study the role of ApoE genotype and Abeta42 in FTLD, as well as establish measures for disease intensity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421130      PMCID: PMC2077590          DOI: 10.1136/jnnp.2005.066043

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

Authors:  H Vanderstichele; E Van Kerschaver; C Hesse; P Davidsson; M A Buyse; N Andreasen; L Minthon; A Wallin; K Blennow; E Vanmechelen
Journal:  Amyloid       Date:  2000-12       Impact factor: 7.141

2.  Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no tau gene mutations.

Authors:  S F Fabre; C Forsell; M Viitanen; M Sjögren; A Wallin; K Blennow; M Blomberg; C Andersen; L O Wahlund; L Lannfelt
Journal:  Exp Neurol       Date:  2001-04       Impact factor: 5.330

3.  Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

Authors:  A J Green; R J Harvey; E J Thompson; M N Rossor
Journal:  Neurosci Lett       Date:  1999-01-08       Impact factor: 3.046

4.  Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease.

Authors:  N Itoh; H Arai; K Urakami; K Ishiguro; H Ohno; H Hampel; K Buerger; J Wiltfang; M Otto; H Kretzschmar; H J Moeller; M Imagawa; H Kohno; K Nakashima; S Kuzuhara; H Sasaki; K Imahori
Journal:  Ann Neurol       Date:  2001-08       Impact factor: 10.422

5.  Abeta peptide 1-42, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia.

Authors:  Lienhard Maeck; Johannes Meller; Markus Otto; Gerthild Stiens; Jens Wiltfang; Gabriela Stoppe
Journal:  Neurosci Lett       Date:  2002-11-15       Impact factor: 3.046

6.  CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging.

Authors:  M Sjögren; L Minthon; P Davidsson; A Clarberg; H Vanderstichele; E Vanmechelen; A Wallin; K Blennow
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

7.  Amyloid beta protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype.

Authors:  D M Mann; A M McDonagh; S M Pickering-Brown; H Kowa; T Iwatsubo
Journal:  Neurosci Lett       Date:  2001-05-25       Impact factor: 3.046

Review 8.  CSF markers for incipient Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel
Journal:  Lancet Neurol       Date:  2003-10       Impact factor: 44.182

9.  Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.

Authors:  M Riemenschneider; S Wagenpfeil; J Diehl; N Lautenschlager; T Theml; B Heldmann; A Drzezga; T Jahn; H Förstl; A Kurz
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

10.  Soluble amyloid beta-protein is increased in frontotemporal dementia with tau gene mutations.

Authors:  Antonella Vitali; Alessandra Piccini; Roberta Borghi; Pantaleo Fornaro; Sandra L Siedlak; Mark A Smith; Pierluigi Gambetti; Bernardino Ghetti; Massimo Tabaton
Journal:  J Alzheimers Dis       Date:  2004-02       Impact factor: 4.472

View more
  2 in total

1.  Tau missing from CSF: a case report.

Authors:  Antonella Alberici; Mario Armani; Anna Paterlini; Luisa Benussi; Francesca Nicosia; Roberta Ghidoni; Simona Signorini; Maria Cotelli; Giovanni B Frisoni; Cristina Geroldi; Carlo P Trevisan; John H Growdon; Barbara Borroni; Alessandro Padovani; Paolo M Rossini; Giuliano Binetti
Journal:  J Neurol       Date:  2007-02-03       Impact factor: 4.849

Review 2.  Biological fluid biomarkers in neurodegenerative parkinsonism.

Authors:  Michael Eller; David R Williams
Journal:  Nat Rev Neurol       Date:  2009-09-01       Impact factor: 42.937

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.